Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease—Author's reply

S. L. Flamm

doi:10.1111/apt.14826

Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease—Author's reply

S. L. Flamm^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	227
Number of pages	1
Journal	Alimentary Pharmacology and Therapeutics
Volume	48
Issue number	2
DOIs	https://doi.org/10.1111/apt.14826
State	Published - Jul 2018

ASJC Scopus subject areas

Gastroenterology
Pharmacology (medical)
Hepatology

Access to Document

10.1111/apt.14826

Cite this

@article{2803e3abc31748c4adf49c260c28af52,

title = "Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease—Author's reply",

author = "Flamm, {S. L.}",

year = "2018",

month = jul,

doi = "10.1111/apt.14826",

language = "English (US)",

volume = "48",

pages = "227",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Editorial

T2 - real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease—Author's reply

AU - Flamm, S. L.

PY - 2018/7

Y1 - 2018/7

UR - http://www.scopus.com/inward/record.url?scp=85048950637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048950637&partnerID=8YFLogxK

U2 - 10.1111/apt.14826

DO - 10.1111/apt.14826

M3 - Editorial

C2 - 29939409

AN - SCOPUS:85048950637

SN - 0269-2813

VL - 48

SP - 227

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 2

ER -

Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease—Author's reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this